Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections

Current antiviral therapies, such as pegylated interferon-α and nucleos(t)ide analogues, effectively improve the quality of life of patients with chronic hepatitis B. However, they can only control the infection rather than curing infected hepatocytes. Complete HBV cure is hampered by the lack of th...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of hepatology Vol. 75; no. 3; pp. 706 - 717
Main Authors:	Martinez, Maria Guadalupe, Boyd, Anders, Combe, Emmanuel, Testoni, Barbara, Zoulim, Fabien
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.09.2021 Elsevier Science Ltd Elsevier
Subjects:	Antiviral agents Antiviral Agents - pharmacology Antiviral Agents - therapeutic use cccDNA chronic hepatitis B Chronic infection Circular DNA Clinical trials direct-acting antivirals DNA, Circular - pharmacology DNA, Circular - therapeutic use HBV cure Hepatitis B Hepatitis B - drug therapy Hepatitis B surface antigen Hepatitis B virus - genetics Hepatocytes Human health and pathology Humans Hépatology and Gastroenterology Interferon Life Sciences Metal-Organic Frameworks - pharmacology Metal-Organic Frameworks - therapeutic use Quality of life Therapeutic targets α-Interferon chronic hepatitis B HBV cure cccDNA direct-acting antivirals
ISSN:	0168-8278, 1600-0641, 1600-0641
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!